Table 3.
Median baseline and six-week changes in metabolic and immuno-inflammatory markers with telmisartan therapy.*
| Week 0 | Week 6 | p-value† | |
|---|---|---|---|
| Total cholesterol (mg/dL) | 166.0 (148.0, 193.0) | 154.0 (138.0, 181.0) | 0.65 |
| LDL cholesterol (mg/dL) | 97.0 (70.0, 111.0) | 90.0 (78.0, 121.0) | 0.34 |
| HDL cholesterol (mg/dL) | 44.4 (38.7, 52.1) | 44.1 (39.7, 49.0) | 0.83 |
| Triglycerides (mg/dL) | 107.0 (80.0, 132.0) | 116.0 (73.0, 141.0) | 0.81 |
| Glucose (mg/dL) | 96.0 (92.0, 104.0) | 97.0 (88.0, 105.0) | 1.0 |
| HOMA-IR score | 2.7 (2.1, 7.0) | 2.6 (1.7, 6.0) | 0.19 |
| Insulin (uU/mL) | 12.1 (9.2, 27.1) | 12.3 (8.2, 19.8) | 0.22 |
| Adiponectin (ng/mL) | 9645.8 (6565.2, 13618.9) | 9560.1 (6195.7, 15841.0) | 0.19 |
| Hyaluronic acid (ng/mL) | 47.0 (33.9, 61.8) | 52.9 (43.1, 80.0) | 0.15 |
| IL-6 (pg/L) | 2.4 (1.5, 3.8) | 2.5 (1.8, 3.7) | 0.96 |
| RANKL (pmol/L) | 155.6 (90.6, 189.8) | 148.4 (62.9, 174.9) | 0.15 |
| OPG (pmol/L) | 6.1 (4.7, 7.3) | 5.4 (4.4, 7.1) | 0.93 |
| RANKL/OPG ratio | 25.4 (16.5, 35.5) | 21.6 (10.6, 37.5) | 0.35 |
| sCD14 (ng/mL) | 1844.5 (1662.4, 2196.4) | 1842.6 (1682.4, 2201.2) | 0.93 |
| sCD163 (ng/mL) | 739.2 (630.9, 1033.4) | 699.3 (613.2, 1005.7) | 0.22 |
| CD8+CD38+HLA-DR+ T lymphocytes (%) | 12.0 (9.7, 15.8) | 10.4 (7.5, 14.7) | 0.17 |
| CD4+CD38+HLA-DR+ T lymphocytes (%) | 11.0 (6.6, 12.5) | 8.8 (6.6, 20.5) | 0.75 |
| CD14+CD16+ monocytes (%) | 4.4 (3.1, 6.8) | 3.7 (2.6, 4.7) | 0.10 |
| CD14+lowCD16+high monocytes (%) | 31.0 (25.6, 54.1) | 37.8 (25.4, 56.2) | 0.89 |
*
Values are expressed as median (interquartile range).
†
Wilcoxon signed rank test value for six-week change.
LDL: low-density lipoprotein, HDL: high-density lipoprotein, HOMA-IR: homeostatic model assessment of insulin resistance, IL-6: interleukin-6, RANKL: receptor activator of nuclear factor-kappa-B ligand, OPG: osteoprotegerin, sCD14: soluble CD14, sCD163: soluble CD163